Latest
28
Jan
GCC Pharmaceutical Industry: Sovereign Wealth Funds and Local Manufacturers
The Gulf Cooperation Council (GCC) pharmaceutical industry is undergoing significant structural changes as sovereign wealth funds deploy capital and local
26 min read
27
Jan
Why Pension Funds Are Investing in Pharmaceutical Royalties
The Pension Fund Challenge—And Why Royalties Address It
Defined benefit pension plans face a structural dilemma: actuarial assumptions of
19 min read
26
Jan
Indication-Specific Royalties in Pharma and Medtech: Structure, Allocation, and Recent Deals
What Are Indication-Specific Royalties?
Indication-specific royalties are royalty financing or licensing arrangements where payments are tied only to sales of
27 min read
25
Jan
The Weekly Term Sheet (2026-W03)
The third week of January, recorded over $10 billion in confirmed and potential transaction value across 30+ biotech, pharmaceutical, and
19 min read
24
Jan
Monetizing Mature Pharmaceutical Assets: Consumer Health, Biosimilars, and Post-LOE Biologics
The pharmaceutical royalty market has deployed over $29 billion since 2020 into patent-protected assets—yet systematically ignores a parallel universe
22 min read
23
Jan
Fund of the week: BCM Europe AG
BCM Europe AG occupies an unusual position in the pharmaceutical financing landscape. The Zug-based investment company has quietly assembled control
17 min read
22
Jan
Company of the week: Proxima Biosciences
Biotechnology startups often promise to "drug the undruggable," but few have embraced that challenge as boldly as Proxima Biosciences.
21 min read
21
Jan
Patent Life and Loss of Exclusivity: Modeling the Royalty Cliff
Patent expiration is the single largest value driver in pharmaceutical royalty valuation, yet most market participants use oversimplified assumptions. Rigorous
13 min read
20
Jan
Gross-to-Net Modeling for Pharmaceutical Royalties: From List Price to Royalty Payment
The GTN Landscape: A $356 Billion Problem Enters a New Era
"Gross-to-net" (GTN) refers to the difference between
13 min read
19
Jan
In Silico Development in the Medical Device Industry
In Silico Medical Device Regulation Reaches Global Inflection Point
The regulatory landscape for computational modeling in medical device development has
9 min read